Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

h being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR(R); reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Contact:
    Michael W. Rogers                    Robin L. DeCarlo
    EVP and Chief Financial Officer      Director, Corporate Communications
    (781) 861-8444                       (781) 402-3405



                        INDEVUS PHARMACEUTICALS, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
             For the three and twelve months ended September 30,
                                2008 and 2007
                 (Amounts in thousands except per share data)

                                         For the three       For the twelve
                                          months ended        months ended
                  
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Genzyme Corporation and Middleton-based Bone Care International Inc. ... fast-tracked their proposed merger. , ,Genzyme and Bone Care have ... Bone Care in an all-cash transaction valued at $33.00 per ... approval by Bone Care's shareholders at a meeting ...
... 151 bypass around Fond du Lac, Wis., opens later ... on a bridge like no other in the country. ... could help to speed bridge-deck construction Externally, the ... the concrete deck reinforced with a novel fiber-reinforced polymer ...
... Commitment. These are the 4 C's that I learned early ... always felt that each "C" was equally important; the folks ... with thick wallets, and so forth. Until a few weeks ... for an organization I love. It was exhilarating: we addressed ...
Cached Biology Technology:Polymer grid technology a boon for bridges 2Polymer grid technology a boon for bridges 3Are boards broken? 2
(Date:12/10/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ) ... Market in Japan 2014-2018" report to their ... The integration of biometrics and smart ... upgradation of the driver,s license is one of ... the aforementioned projects, biometrics is being used as ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... C-Labs LLC, a leading provider of remote ... today announced the appointment of John Traynor ... strategic advisor to the firm, Mr. Traynor will now ... based out of the C-Labs office in ... Muench , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... often thought of as a domesticated animal, one that may ... the wilderness of North America, are thought of as conducting ... the journal Nature Climate Change suggests that there ... and change in climate played a role in their evolution. ...
... macrophages, the immune system,s healthy scavenger cells, play a key ... other areas of the body, according to research to be ... Biology annual meeting in New Orleans. The researchers, ... Health & Science University (OHSU) in Portland followed the work ...
... in Alzheimer,s disease (AD) has focused on whether the protein ... cause of the disease. But George Bloom, Ph.D., and ... hypothesis: much earlier interactions between the two proteins them drive ... (CCR). Dr. Bloom will present additional evidence supporting ...
Cached Biology News:Climate change will endanger caribou habitat, study says 2Spontaneous fusion with macrophages empowers cancer cells to spread 2Uncovering first molecular missteps that drive neurons in pathway leading to Alzheimer's disease 2
... Partek Genomics Solution is a comprehensive ... data visualization specifically designed to reliably ... for high-dimensional genomic studies containing thousands ... fast, memory efficient and will analyze ...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
Intestinal Epithelium Differentiation Environment...
Biology Products: